yuhan corp -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- downgrad neutral
review downgrad neutral given prolong recoveri phase
yuhan consolid op miss expect api
manufactur subsidiari deepen loss inventori write-off vs
hope recoveri api sale came soft yoy
albeit pharma sustain growth yoy
alter view yuhan consolid earn remain
soft recoveri phase seem prolong pharma
divis show progress given focu top-line
 api remain soft would take time recov
drag consolid earn growth yuhan-
kimberli jv growth remain soft weigh np
downgrad neutral revis api division growth
yoy vs yoy previous tp cut
cut ep
retain target multipl price-to-earnings histor high-end
 momentum sustain given recent license-out agreement
mn expect on-going progress
year-end lazertinib trial remain track
estimate pot chg tp
 chang prev ep
note yuhan corp manufactur market variou pharmaceut product
partnership global pharmaceut compani compani also produc
person care product etc affili
click detail financi
reviewbig miss due subsidiari loss
yuhan consolid op miss expect api
manufactur subsidiari yuhan chem deepen
loss inventori write-off vs hope recoveri recal yuhan
export hcv product liver diseas api gilead end-
demand collaps sinc api sale came soft
yoy albeit pharma sustain growth yoy
addit event api remain soft yoy would
take time recov drag consolid earn
growth yuhan-kimberli jv household product
growth remain soft weigh np china export continu
weaken yoy amid unexcit domest growth yoy
face inventori adjust cycl due prolong weak end-demand
downgrad neutral await momentum build
revis api division growth yoy vs
yoy previous estim account
op tp cut cut ep
howev retain target multipl price-to-earnings histor high-
end momentum sustain given recent license-out agreement
mn degen disc diseas first-in-class
candid yet dont factor pipelin valu given minim
contribut bn adjust total mileston probabl
success rate expect on-going progress
year-end lazertinib lung cancer trial remain track
wait dust settl
alter view yuhan consolid earn remain
soft recoveri phase seem prolong pharma
divis show progress given focu top-line
yoy recent license-out sustain momentum
seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid
report singl factor make invest decis
chem opm lh yuhan chem annual inventori day rh margin inv forward consensu p/eavg lack pipelin amid market favor d-driven playersre-ratingdriven momentum build lazertinib charl tineau pm univers toronto
compani mention price
ray certifi view express report accur reflect person view subject compani secur
part compens directli indirectli relat specif recommend view express report
